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A B S T R A C T
Kyotorphin is a unique biologically active neuropeptide (L-tyrosine-L-arginine), which is reported to have opioid-
like analgesic actions through a release of Met-enkephalin from the brain slices. N-methyl-L-tyrosine-L-arginine
(NMYR), an enzymatically stable mimetic of kyotorphin, successfully caused potent analgesic effects in thermal
and mechanical nociception tests in mice when it was given through systemic routes. NMYR analgesia was
abolished in μ-opioid receptor-deficient (MOP-KO) mice, and by intracerebroventricular (i.c.v.) injection of
naloxone and of N-methyl L-leucine-L-arginine (NMLR), a kyotorphin receptor antagonist. In the Ca2+-mobili-
zation assay using CHO cells expressing Gαqi5 and hMOPr or hDOPr, however, the addition of kyotorphin neither
activated MOPr-mechanisms, nor affected the concentration-dependent activation of DAMGO- or Met-
Enkephalin-induced MOPr activation, and Met-enkephalin-induced DOPr activation. NMYR-analgesia was sig-
nificantly attenuated in preproenkephalin (PENK)- or proopioimelanocortin (POMC)-KO mice. The systemic
administration of arginine, which is reported to elevate the level of endogenous kyotorphin selectively in
midbrain and medulla oblongata, pain-related brain regions, caused significant analgesia, and the analgesia was
reversed by i.c.v. injection of NMLR or naloxone. In addition, PENK- and POMC-KO mice also attenuated the
arginine-induced analgesia. All these findings suggest that NMYR and arginine activate brain kyotorphin re-
ceptor in direct and indirect manner, respectively and both compounds indirectly cause the opioid-like analgesia
through the action of endogenous opioid peptides.
1. Introduction
Kyotorphin is an analgesic dipeptide (L-tyrosine-L-arginine), which
was isolated from bovine brain by use of in vivo analgesic assay system
[1]. As kyotorphin causes an in vitro release of Met-enkephalin from the
striatal slices [1,2], but shows neither binding activity to opioid re-
ceptors nor inhibiting activity of enkephalin degrading enzymes
[1,3,4], this dipeptide is known as an enkephalin releaser. Although
details remain elusive, there are several studies showing that opioid
receptor antagonist, naloxone blocked various pharmacological or
physiological actions of kyotorphin [5,6,3,7]. Kyotorphin was found to
bind to putative Gi-coupled receptor in brain membranes through re-
constitution experiments using purified Gi1 and membrane putative
receptor, which has high-affinity to [3H]-kyotorphin [8]. It should be
noted that L-leucine-L-arginine (Leu-Arg) inhibits the [3H]-kyotorphin
binding and kyotorphin-induced GTPase activation, a sign of G-protein
activity, but Leu-Arg has no agonist activity on G proteins [8], sug-
gesting that Leu-Arg could be considered as a pure kyotorphin receptor
antagonist [9,10]. Regarding the biosynthesis, we have reported that
kyotorphin is synthesized from L-tyrosine and L-arginine by partially
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purified synthetase from rat brains, and the distribution and subcellular
localization of the synthetase [11] are similar to those of kyotorphin
[12]. However, the possibility cannot be excluded that this dipeptide is
generated by the enzymatic processing of precursor proteins [13]. Most
recently we have reported that tyrosyl-tRNA synthetase is a potential
kyotorphin synthetase and has similar biochemical characteristics to
partially purified rat kyotorphin synthetase [14]. Based on the finding
that Km value for substrate arginine is much higher than the plasma
concentration [11,14], we examined the change in brain kyotorphin
levels following the systemic administration of arginine. The elevation
of kyotorphin contents was uneven throughout brain regions [14], and
it was higher in the midbrain and medulla oblongata, being consistent
to the brain regional distribution of partially purified kyotorphin syn-
thetase in the rat brain [11]. Kawabata et al. [15] reported that the
systemic administration with L-arginine inhibited the carrageenan-in-
duced inflammatory hyperalgesia, being consistent to the character-
ization of kyotorphin synthetase.
Through various attempts to design stable and potent derivatives of
kyotorphin, we found an N-methyl-derivative NMYR has promising
potencies in a unique and very sensitive peripheral nociception test
[16]. In that study, the intraplantar injection of sub-femtomoles of
NMYR caused nociceptive responses, which was reversed by the co-
administration of similar dose of kyotorphin antagonist N-methyl-Leu-
Arg, NMLR. Following this study, several papers have reported that
kyotorphin-amide modification and its derivatives successfully show
enzymatical stability and potent analgesic activity even by systemic
administration [17,18], though no attempt has been done to examine
whether kyotorphin-amide analgesia is blocked by kyotorphin antago-
nist, Leu-Arg or NMLR. Regarding the characterization as 'opioid-like'
analgesia, they used intrathecal injection (i.t.) of naloxone, an opioid
receptor antagonist to demonstrate the opioid-like analgesia of kyo-
torphin-amide [17]. However, as this report lacks the data with a high
dose (50 μg) of naloxone (i.t.) alone, it remains elusive how much the
possible hyperalgesic actions of naloxone affected the analgesic action
of kyotorphin-amide. In addition, the attempt to see involvement of
brain opioid mechanisms through endogenous opioid peptides also re-
mains to be determined with the analgesia of kyotorphin derivatives.
In the present study we aimed to first examine whether potent an-
algesic is obtained by the systemic administration of NMYR that we
have previously developed [16]. Secondly, we attempted to pharma-
cologically characterize the analgesic effects NMYR and arginine in
terms of the involvement of brain opioid peptides using mice deficient
of preproenkephalin (PENK) or proopioimelanocortin (POMC) gene, as
well as in vivo NMLR antagonism and in vivo and/or in vitro opioid
receptor-involvements.
2. Materials and methods
2.1. Materials
Synthetic peptides, kyotorphin, NMYR and NMLR were purchased
from PH Japan Co., Ltd. (Hiroshima, Japan). [D-Ala2, N-Methyl-Phe4,
Gly5-ol] enkephalin (DAMGO) and naloxone hydrochloride was pur-
chased from Sigma Aldrich (St. Louis, MO), Met-enkephalin and L-ar-
ginine were from WAKO (Osaka, Japan). In in vivo experiments, NMYR
was administered through subcutaneous (s.c.), per os (p.o.), in-
tracerebroventricular (i.c.v.) or intrathecal (i.t.) routes, while NMLR
was given by i.c.v. or i.t. injection. For the culture experiments to see
opioid receptor signaling, DMEM/HAM-F12 medium, geneticine, hy-
gromycin B were purchased from Wako, Hank’s Balanced Salt Solution
(HBSS) and pluronic acid were from Life Technologies (Grand Island,
NY), Fluo-8 was from AAT Bioquest (Sunnyvale, CA), amaranth, pro-
benecid, and DAMGO were from Sigma Aldrich.
2.2. Animals
Male C57BL/6 J mice (15–30 g) were purchased from TEXAM
(Nagasaki, Japan) and used for most of experiments. Animals were
housed in a room maintained at 22 ± 3 °C and 55 ± 5% relative hu-
midity with a 12 h light/dark cycle (light on 8:00 A.M. to 8:00 P.M.).
Food and water were available ad libitum. In some experiments, male μ
opioid receptor (MOPr) gene-deficient (MOPr-KO) mice, which had
been kindly supplied by Brigitte Kieffer (McGill Univ. Douglas Institute,
Montreal, Canada) and backcrossed to the inbred C57BL/6J mice for at
least 10 generations were used, as reported previously [19]. In some
other experiments, we used male preproenkephalin-deficient (PENK-
KO) mice and proopiomelanocortin-deficient (POMC-KO) mice from
The Jackson Laboratory (Bar Harbor, ME) possessing C57BL/6J and
129S2/SvPas mixed genetic background, as reported previously [20].
These mice were backcrossed to the inbred C57BL/6J mice for at least
10 generations before using for behavioral experiments. All procedures
were approved by the Nagasaki University Animal Care Committee
(Nagasaki, Japan) and complied with the recommendations of the In-
ternational Association for the Study of Pain [21]. All studies involving
animals are reported in accordance with the ARRIVE guidelines for
reporting experiments involving animals [22–24].
2.3. Nociception tests
Thermal paw withdrawal, paw pressure and tail-flick tests were
performed as, previously reported [25–27]. In some experiments, the
analgesic activities were evaluated by use of area under the curve
(AUC) as described in figure legends (Figs. 3 and 4).
2.4. Cells
The CHO cells stably co-expressing human μ opioid receptor
(hMOPr) and C-terminal modified Gαq chimeric G protein, in which last
5 amino acids of C-terminal Gαq were replaced by corresponding Gαi
amino acids to make Gαqi5, and the CHO cells stably co-expressing
human δ opioid receptor (hDOPr) and C-terminal modified Gαq chi-
meric G protein, in which last 5 amino acids of C-terminal Gαq with
G66D mutation were replaced by corresponding Gαi amino acids to
make GαqG66Di5. Both CHO cells expressing hMOPr and Gαqi5 or hDOPr
and GαqG66Di5 were prepared, as reported [28], and generously given
by Dr. Girolamo Calo at University of Ferrara, Italy. These cells were
maintained with DMEM/HAM-F12 supplemented with 10% FBS,
200 μg/mL of geneticine, 100 μg/mL of hygromycin B, 100 IU/mL pe-
nicillin and 100 IU/mL streptomycin, and incubated at 37 °C in a 5%
CO2 atmosphere.
2.5. Ca2+ mobilization assay
Ca2+ mobilization assay using the CHO cells (CHOhMOP-Gαqi5 and
CHOhDOP-GαqG66Di5) was previously described [29]. Briefly, CHOhMOP-
Gαqi5 and CHOhDOP-GαqG66Di5 cells were harvested using 0.5mM EDTA,
centrifuged, and re-suspended in culture medium described above. The
cells were plated on a 384-well plate at the density of 1.0× 104 cells/
well/30 μL. Following overnight incubation, the medium was removed
and the cells were loaded with 3 μM Fluo-8 dissolved in 20mM HEPES/
HBSS solution (pH7.4) containing 1mg/mL amaranth, 2.5mM probe-
necid, and 0.01% pluronic acid. After 1 h incubation, the cells were
stimulated with either 10 μM kyotorphin or vehicle for 5min. Then,
Met-enkephalin or DAMGO at defined concentrations was added to the
cells in the presence or absence of 10 μM kyotorphin. The fluorescence
was recorded by Functional Drug Screening System/μCell (Hamamatsu
Photonics K.K., Hamamatsu, Japan) and the fluorescence intensity was
described as signal ratio (tested value/basal value) or fold induction.
Dose-response curves were plotted as mean ± S.E.M using GraphPad
prism (Graphpad Software. San Diego, CA).
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2.6. Statistical analysis
All Data were presented as means ± S.E.M. and analyzed using the
GraphPad prism 7.0. Data were analyzed using the unpaired t-test, one-
way ANOVA followed by Tukey’s or Dunnett’s multiple comparisons
test and two-way ANOVA followed by Tukey’s or Bonferroni’s multiple
comparisons test. The criterion of significance was significance was set
up at P < 0.05.
3. Results
3.1. Potent analgesic effects of NMYR by systemic injection
An enzymatically stable kyotorphin derivative NMYR [16] at a dose
of 30mg/kg (s.c.) showed potent analgesic effects with peak effects at
45 min in the thermal paw withdrawal test, and the analgesic action
was completely disappeared at 90min, the significant analgesic effects
of NMYR were observed at as low as 3mg/kg (s.c.), and there was a
dose-dependency in the range of 3–30mg/kg (s.c.), as shown in Fig. 1
A, B . Similar potent dose-dependent analgesic effects of NMYR were
also observed by the administration through a per os (p.o.) route
(Fig. 1C, D). The peak effects at 100mg/kg (p.o.) were 1.5 h and the
analgesic effects lasted for 3 h. In the tail-flick test, another thermal
nociception test, systemic NMYR showed potent analgesia, which lasted
for 90min with a dose-dependency in the range of 10–100mg/kg, s.c.
(Fig. 1E, F). Similar potent analgesia was also observed in the paw
pressure test (Fig. 1G, H).
3.2. Antagonism of NMYR-induced analgesia by a putative antagonist
NMLR and naloxone
When 3 nmol of NMYR was given i.c.v., significant analgesic effect
at 15 and 30min, and dose-dependent effects were observed in the
range of 0.3–3 nmol in the thermal paw withdrawal test (Fig. 2 A, B).
However, the analgesia by NMYR given i.t. was less potent, and short-
acting even with 10 nmol (Fig. 2C, D). A kyotorphin receptor antago-
nist, NMLR [16] at doses of 0.3–3 fmol (i.c.v.) blocked the NMYR
(30mg/kg, s.c.)-induced analgesia in a dose-dependent manner
(Fig. 2E). Significant, but partial antagonism of NMYR (s.c.)-analgesia
was also observed by i.t. injection of NMLR at 30 fmol (Fig. 2F). The
NMYR (s.c.)-analgesia was also abolished by naloxone at as low as
0.1 nmol (approximately 40 ng, i.c.v.), which alone has no effect on the
basal threshold.
3.3. Involvement of brain opioid peptides in NMYR-induced analgesia
The analgesia by 30mg/kg (s.c.) of NMYR in the thermal paw
withdrawal test was abolished in MOPr-KO mice (Fig. 3A, B). The an-
algesic effects of NMYR (30mg/kg, s.c.) were also inhibited in PENK-
KO mice (Fig. 3C). Quantitative analysis using AUC at periods of
15–75min showed that NMYR analgesic activity was significant atte-
nuated by approximately 20% in PENK-KO mice (Fig. 3D). Similar at-
tenuation of NMYR analgesia by approximately 25% of AUC was ob-
served in POMC-KO mice (Fig. 3E, F).
As shown in Fig. 3G, kyotorphin in the range of 0.1 nM to 10 μM has
no agonist activity in MOPr-expressing cells. The addition of 10 μM
kyotorphin did not affect the concentration-dependent Ca2+-mobiliza-
tion responses by DAMGO, a selective MOPr agonist (Fig. 3H). The
EC50 of DAMGO in the absence or presence of kyotorphin was
1.8 ± 0.07 nM (n= 4), and 1.9 ± 0.1 nM (n=4), respectively. Si-
milarly, the EC50 of Met-enkephalin in the absence or presence of
10 μM kyotorphin was 1.3 ± 0.08 nM (n=4), and 2.1 ± 0.02 nM
(n= 4), respectively (Fig. 3I). Furthermore, 10 μM kyotorphin also has
no allosteric effects on DOPr-expressing cells (Fig. 3J). EC50 of Met-
Fig. 1. Analgesic effects of NMYR given through systemic administration.
(A–D): Time course (A, C) and dose-dependency (B, D) of analgesia in the thermal paw withdrawal test after the s.c. (A, B) or p.o. (C, D) injection of NMYR or saline.
Results represent the paw withdrawal latency (PWL) in seconds (s). The number of parenthesis indicates the number of mice used. In the dose-dependency test, the
data show the mean ± S.E.M. E–H: Time course (E, G) and dose-dependency (F, H) of NMYR (s.c.)-induced analgesia in the tail-flick test (E, F) or paw pressure test
(G, H). A, C, E, G: *P < 0.05, vs. saline at each time point, two-way ANOVA followed by Bonferroni’s multiple comparisons test. B, D, F, H: *P < 0.05, vs. dose 0
(means saline injection), one-way ANOVA followed by Dunnett’s multiple comparisons test.
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enkephalin in the absence or presence of kyotorphin was
0.53 ± 0.05 nM (n=4), and 0.47 ± 0.04 nM (n=4), respectively.
3.4. Involvements of kyotorphin receptor and endogenous opioid peptides in
arginine-induced analgesia
As we have recently observed that the L-arginine-treatment in-
creases brain levels of kyotorphin [14], we tested whether this treat-
ment shows the analgesia and its mechanism is related to brain opioid
system. As shown in Fig. 4A, the systemic L-arginine treatment at a dose
of 1 g/kg (p.o.) showed potent analgesia with a peak effect at 1.5 h in
the thermal paw withdrawal test. The analgesia was dose-dependent in
the range of 0.1–1 g/kg (p.o.) of L-arginine (Fig. 4B). The analgesia by
1 g/kg (p.o.) of L-arginine was completely abolished by i.c.v. injection
of NMLR (Fig. 4C) and naloxone (Fig. 4D). Furthermore, the analgesia
was significantly attenuated in PENK-KO mice by 46% (Fig. 4E, F), and
in POMC-KO mice by 36% (Fig. 4G, H) by use of quantitative analysis
using AUC (1–2 h).
4. Discussion
The first issue to note is the experimental evidence that N-methyl
derivatives of neuro-dipeptide kyotorphin (NMYR) and its antagonist
NMLR pharmacologically behave as enzymatically stable and potent
kyotorphin receptor agonist and antagonist, respectively, being con-
sistent to our previous report using peripheral nociception test [16].
The present study revealed that systemic administration of NMYR,
through s.c. or p.o. routes has potent analgesic actions in various
thermal and mechanical nociception tests, though systemic kyotorphin
administration has no significant analgesic action (data not shown).
The enhancement of analgesia by N-methylation was consistent to the
previous report using kyotorphin-amide [30]. The analgesic action of
NMYR was reproduced largely by brain (i.c.v.) injection, but weakly by
spinal (i.t.) injection. As the brain administration of antagonist NMLR in
the dose range of as low as 0.3–3 fmol, blocks the systemic NMYR (s.c.)-
induced analgesia, while the spinal (i.t.) administration at 30 fmol
showed a blockade at the level less than the case with 1 fmol (i.c.v.), the
major mechanisms appear to be attributed to the brain actions. The
second issue to note is the experimental evidence that NMYR exerts
analgesic effects through brain endogenous opioids. The analgesia by
NMYR was abolished in MOPr-KO mice and by naloxone (i.c.v.), being
consistent to the previous observation that naloxone blocks the an-
algesia induced by kyotorphin given through an i.c.v. or intracisternal
route [1].
The present study kyotorphin did not activate MOPr-mechanisms in
the Ca2+-mobilization assay using CHO cells expressing hMOPr and
Gαqi5. Furthermore, as kyotorphin did not affect the concentration-
dependent activation of DAMGO- or Met-enkephalin-induced MOPr
activation, and also did not affect Met-enkephalin-induced DOPr acti-
vation, it appears that this dipeptide also has neither direct nor indirect
action through positive allosteric modulation to opioid receptors, un-
like the cases with opioid mimetics [31,32]. In addition, there are re-
ports that kyotorphin failed to inhibit enkephalin-degrading enzymes
[4,33]. Thus, promising mechanisms would be the release of en-
dogenous opioids, such as Met-enkephalin or β-endorphin, since NMYR-
induced analgesia was attenuated in PENK- or POMC-KO mice, though
each blockade seems to be insufficient for complete blockade in the
quantitative analysis using AUC by 21 or 25%, respectively. Thus, it is
interesting to examine whether NMYR analgesia is fully reversed in
PENK- and POMC-double KO mice. There are reports that POMC con-
tains adrenocorticotropic hormone and α-melanocyte stimulating hor-
mone have anti-opioid activities [34,35]. Accordingly, the loss of anti-
opioid activities may attenuate the blockade of NMYR analgesia due to
the loss of β-endorphin in POMC-KO mice. Furthermore, as often dis-
cussed in many other cases with KO mice, it is also possible that em-
bryonic deficiency of POMC or PENK gene may cause compensational
machineries to make up the lost functions during development.
We have previously described a partially purified kyotorphin syn-
thetase, an enzyme catalyzing the chemical reaction: L-tyrosine+ L-
arginine+ATP → kyotorphin+AMP+PPi in the presence of Mg2+.
The Km values for L-tyrosine and L-arginine are 25.6 μM and 926 μM,
respectively [11]. As plasma levels of L-tyrosine and L-arginine are both
50–100 μM [36], the levels of L-arginine may be a rate-limiting sub-
strate. Based on this fact, Kawabata et al. [15] reported that the sys-
temic administration with L-arginine inhibited the carrageenan-induced
inflammatory hyperalgesia in a Leu-Arg (i.c.v.)-reversible manner. The
Fig. 2. Brain mechanisms of NMYR-induced analgesia.
All experiments in this figure were performed in the thermal paw withdrawal test. (A–D): Time course (A, C) and dose-dependency (B, D) of analgesia in the thermal
paw withdrawal test after i.c.v. (A, B) or i.t. (C, D) injection of NMYR or aCSF. E, F: Potent or weak antagonism by i.c.v. (E) or i.t. (F) injection of NMLR against the
systemic NMYR-induced analgesia. (G) Antagonism of NMYR (s.c.)-induced analgesia in the thermal paw withdrawal test by naloxone (i.c.v.). Other details are
shown in the legends of Fig. 1A. (C): *P < 0.05, vs. saline at each time point, two-way ANOVA followed Bonferroni’s multiple comparisons test. (B, D): *P < 0.05,
one-way ANOVA followed by Dunnett’s multiple comparisons test. (E, F, G): *P < 0.05, one-way ANOVA followed by Tukey’s multiple comparisons test.
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present study using naïve mice supported these findings, and NMLR
(i.c.v.) as well as naloxone (i.c.v.) completely reversed L-arginine (p.o.)-
induced analgesia in naive mice, suggesting the involvement of en-
dogenous kyotorphin and opioids in the brain.
Thus, necessary future approach to clarify the involvement of β-
endorphin or Met-enkephalin in the NMYR-analgesia would be the
identification of brain loci responsible NMYR-induced endogenous
opioid release for the study of the direct measurement of opioid peptide
release through microdialysis probe or push-pull cannula. To be suc-
cessful in this strategy, we need to first identify the brain loci re-
sponsible for NMYR-actions, e.g. through an experiment to measure the
NMYR-activated 35S-GTPγS binding and its reversibility by NMLR,
using brain slices.
As NMYR is a smallest peptide, it could be a promising prototype to
be developed as pharmaceutical compound in terms of synthetic costs
and drug-delivery system. NMYR shows analgesic activity through en-
dogenous opioids, which have no ceiling effects, unlike non-steroidal
anti-inflammatory drugs or acetoaminophen. Therefore, better-mod-
ified kyotorphin mimetics would be added to a compound group useful
at the first stage of three-step analgesic ladder for cancer pain relief
proposed by world health organization.
In conclusion, we successfully confirmed the unique analgesic me-
chanisms of kyotorphin by use of more stable and potent derivative,
NMYR. Additional findings were observed in the experimental evidence
that NMLR behaves as a kyotorphin receptor antagonist, and that
opioid-like NMYR-analgesia was inhibited by naloxone (i.c.v.), and in
MOPr-KO and opioid peptides-KO mice. Better kyotorphin mimetics in
terms of potency and pharmacokinetics/pharmacodynamics would be
promising as supportive drugs for cancer pain relief.
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